Analysts Set Synlogic Inc (NASDAQ:SYBX) Target Price at $12.07

Shares of Synlogic Inc (NASDAQ:SYBX) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.07.

A number of equities research analysts have weighed in on the stock. Citigroup cut shares of Synlogic from a “buy” rating to a “sell” rating and cut their price objective for the stock from $20.00 to $2.00 in a report on Wednesday, August 21st. Zacks Investment Research upgraded shares of Synlogic from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Saturday, November 16th. Chardan Capital reiterated a “buy” rating on shares of Synlogic in a report on Thursday, September 19th. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price target (down previously from $10.00) on shares of Synlogic in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Synlogic in a report on Monday, September 9th.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Synlogic by 0.3% during the second quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock valued at $7,013,000 after buying an additional 2,558 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Synlogic by 11.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 3,708 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Synlogic during the third quarter valued at approximately $34,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Synlogic during the second quarter valued at approximately $195,000. Finally, Northern Trust Corp grew its holdings in shares of Synlogic by 17.1% during the second quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock valued at $1,835,000 after buying an additional 29,401 shares during the last quarter. Hedge funds and other institutional investors own 61.00% of the company’s stock.

SYBX traded up $0.27 during midday trading on Thursday, reaching $2.74. The company’s stock had a trading volume of 747,245 shares, compared to its average volume of 174,661. The firm has a market capitalization of $88.48 million, a price-to-earnings ratio of -1.35 and a beta of 2.55. The company has a current ratio of 12.70, a quick ratio of 12.70 and a debt-to-equity ratio of 0.14. Synlogic has a 1 year low of $1.91 and a 1 year high of $11.43. The stock’s 50-day moving average is $2.21 and its 200-day moving average is $4.55.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.09. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.46 million. Synlogic had a negative net margin of 4,574.82% and a negative return on equity of 34.49%. As a group, equities research analysts forecast that Synlogic will post -1.81 earnings per share for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: Asset Allocation and Your Retirement

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.